Wells Fargo (NYSE: WFC) initiated coverage on BlackRock (NYSE: BLK) with an "Overweight" rating, citing a "nice entry point" for the investment manager. Analysts anticipate significant growth...
Nike surpassed EPS estimates but reported a r...
NETSOL Technologies is set to report Q1 2027 ...
Corteva (NYSE: CTVA), OpenWorld (NASDAQ: OPNW), Nektar Therapeutics (NASDAQ: NKTR), Agomab Therapeutics (NASDAQ: AGMB), and Agenus (NASDAQ: AGEN) posted steep one-day losses on October 1, 2026. Most o
On October 1, 2026, Nexalin Technology (NASDAQ: NXL), Armada Acquisition Corp. II (NASDAQ: XRPN), Roze AI (NASDAQ: RZAI), Mattel (NASDAQ: MAT), and Accenture (NYSE: ACN) led stock market gainers on he
Jefferies analyst Roger Song has set a significant $150 price target for Nektar Therapeutics (NASDAQ: NKTR), indicating substantial potential upside for the biotech stock. Despite promising Phase IIb
A new union contract for Boeing (NYSE: BA) removes near-term risk to its 737 production, boosting investor confidence. The agreement with its largest white-collar union avoids a potential str
Neogen (NASDAQ: NEOG) is expected to report fiscal first-quarter earnings on October 6, 2026, although reports differ on the exact release timing. Analysts expect adjusted EPS of about $0.05, while r
Stifel cut its price target for Foghorn Therapeutics after a major partnership update with Eli Lilly. Foghorn and Eli Lilly will not advance FHD-909 or a separate selective SMARCA2 degrader program.
